GICS Sector : Healthcare
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases.Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease.The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
Feb -20
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
Dec -20
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Nov -21
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Nov -14
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
Aug -23
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
Aug -22
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH
Aug -22
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
Aug -15
Cyclo Therapeutics' Cyclodextrin-based products' 10.27% growth is driven by increasing demand for novel drug delivery systems, growing adoption in pharmaceutical and biotechnology industries, and rising research activities in cyclodextrin-based nanomedicine. Additionally, expanding applications in food, cosmetics, and pharmaceutical industries, as well as strategic partnerships and collaborations, contribute to the segment's growth.
A proprietary formulation of hydroxypropyl beta cyclodextrin, used to treat Niemann-Pick disease type C, a rare genetic disorder.
A formulation of hydroxypropyl beta cyclodextrin, being developed as a potential treatment for Alzheimer's disease.
A proprietary formulation of hydroxypropyl beta cyclodextrin, used to treat Niemann-Pick disease type C1, a rare genetic disorder.
Cyclo Therapeutics, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for Niemann-Pick disease.
Patients and caregivers have limited bargaining power due to the rarity of Niemann-Pick disease and the lack of available treatment options.
Cyclo Therapeutics, Inc. has a moderate bargaining power of suppliers due to the limited number of suppliers of raw materials and equipment.
The threat of new entrants is low due to the high barriers to entry, including the need for specialized expertise and significant investment in research and development.
The intensity of rivalry is high due to the presence of established pharmaceutical companies and biotechs developing treatments for Niemann-Pick disease.
| Value | |
|---|---|
| Debt Weight | 17.84% |
| Debt Cost | 3.95% |
| Equity Weight | 82.16% |
| Equity Cost | 3.07% |
| WACC | 3.22% |
| Leverage | 21.72% |
Value: 10.0
Growth: 1.8
Quality: 8.3
Yield: 0.0
Momentum: 10.0
Volatility: 0.0
1-Year Total Return ->
Value: 8.4
Growth: 3.9
Quality: 5.5
Yield: 0.0
Momentum: 8.0
Volatility: 1.7
1-Year Total Return ->
Value: 8.0
Growth: 3.4
Quality: 5.0
Yield: 0.0
Momentum: 5.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.9
Growth: 2.3
Quality: 5.2
Yield: 0.0
Momentum: 5.0
Volatility: 0.3
1-Year Total Return ->
Value: 7.3
Growth: 4.8
Quality: 5.0
Yield: 0.0
Momentum: 0.5
Volatility: 1.7
1-Year Total Return ->
Value: 6.4
Growth: 4.2
Quality: 3.4
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->